Group 1 - The company held its third meeting of the seventh Supervisory Board on August 21, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [1] - The Supervisory Board approved the 2025 semi-annual report, confirming it accurately reflects the company's financial status and operational results without any false statements or omissions [2] - The company plans to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares, totaling approximately 23,014,379.00 yuan (including tax) based on a total share capital of 230,143,790 shares as of June 30, 2025 [2][3] Group 2 - The Supervisory Board approved the provision for asset impairment, amounting to 6,985,704.19 yuan, based on a cautious assessment of assets that may show signs of impairment [3] - The company agreed to cancel the Supervisory Board, transferring its powers to the Audit Committee of the Board of Directors, and will amend the company’s articles of association accordingly [4] - All proposals from the Supervisory Board will be submitted for approval at the upcoming shareholders' meeting [5]

Overview - The company announced the provision for asset impairment for the first half of 2025, totaling 8.1683 million yuan [1][3][4] Asset Impairment Provision Details - The total provision for asset impairment includes 3.3103 million yuan for credit impairment and 4.8580 million yuan for asset impairment [1][2] - Breakdown of credit impairment provision: - Accounts receivable bad debt provision: 3.4156 million yuan - Notes receivable bad debt provision: 0.0109 million yuan - Other receivables bad debt provision: -0.1162 million yuan [1][2] - The asset impairment provision is entirely attributed to inventory write-downs, amounting to 4.8580 million yuan [1][2] Impact on Financials - The total provision of 8.1683 million yuan will reduce the company's total profit for the first half of 2025 by the same amount (unaudited) [3][4] - The provision is made based on the principle of prudence and complies with relevant accounting standards, reflecting the company's financial status accurately [3][4][5] Governance and Approval - The provision was approved by the company's board of directors and supervisory committee, ensuring compliance with legal and regulatory requirements [4][5] - The audit committee confirmed that the provision is based on actual asset conditions and adheres to accounting policies [4][5]

Summary of Key Points Core Viewpoint - The company announced the provision for asset impairment for the first half of 2025, totaling 9.6127 million yuan, to reflect its financial status and operating results accurately as of June 30, 2025 [1][3]. Group 1: Asset Impairment Provision Overview - The company conducted an asset impairment test and provisioned for credit impairment and asset impairment losses based on the prudence principle, amounting to a total of 9.6127 million yuan for the first half of 2025 [1][3]. - The breakdown of the impairment provision includes a credit impairment loss of 0.7452 million yuan and an asset impairment loss of 8.8675 million yuan [2][3]. Group 2: Specifics of the Impairment Provision - For receivables, the company recognized a credit impairment loss of 0.7452 million yuan based on expected credit losses from various receivables [2]. - For inventory, the company recognized an inventory impairment loss of 8.8675 million yuan, as the cost of inventory exceeded its net realizable value [3]. Group 3: Impact on Financial Statements - The total provision for credit and asset impairment losses will reduce the company's profit before tax by 9.6127 million yuan for the first half of 2025 [3]. - The provision is in compliance with the relevant accounting standards and reflects the company's actual financial situation without harming the interests of shareholders [3][4]. Group 4: Review and Approval Process - The Audit Committee, Board of Directors, and Supervisory Committee all reviewed and approved the asset impairment provision, confirming that it adheres to accounting standards and company policies [4].

Summary of Key Points Core Viewpoint - The company announced a provision for asset impairment totaling RMB 65,839,286.55 for the first half of 2025, reflecting a significant adjustment in its financial statements to accurately represent its asset status and operational results [1][6]. Group 1: Asset Impairment Details - The total asset impairment provision includes credit impairment losses of RMB 32,334,953.25 and asset impairment losses of RMB 33,504,333.30 [1][2]. - The breakdown of credit impairment losses includes accounts receivable bad debt losses of RMB 48,182,480.14 and a reversal of bad debt losses on notes receivable amounting to RMB 15,847,526.89 [2][3]. - The asset impairment losses consist of inventory write-downs and contract performance cost impairment losses totaling RMB 33,297,032.69, along with contract asset impairment losses of RMB 214,315.56 [5]. Group 2: Accounting Policies and Procedures - The company follows specific accounting policies for measuring credit losses based on the present value of expected cash shortfalls, applying these policies to both notes receivable and accounts receivable [2][3]. - For contract assets, the company measures expected credit losses based on the aging of the contract assets, ensuring that the provisions reflect the actual risk associated with these assets [4][5]. - The decision to recognize these impairments was reviewed and approved by the Audit Committee and the Board of Directors, confirming compliance with relevant accounting standards and regulations [6].

Core Viewpoint - The board of directors of Dongguan Kaige Precision Machinery Co., Ltd. has approved the 2025 semi-annual report and related documents, confirming their compliance with legal and regulatory requirements, and asserting the accuracy and completeness of the information presented [1][2]. Group 1: Board Meeting Resolutions - The board meeting held on August 21, 2025, was legally convened with all five directors present, and the resolutions passed were deemed valid [1]. - The 2025 semi-annual report and its summary were approved, reflecting the company's actual situation without any false statements or omissions [1][2]. - The special report on the use of raised funds for the first half of 2025 was also approved, confirming compliance with relevant regulations and the absence of any misuse of funds [2]. Group 2: Financial Management Decisions - The board approved the use of up to RMB 400 million of idle raised funds for cash management, allowing investment in high-security and liquid financial products, with a validity period of 12 months [3]. - The board's decision to recognize asset impairment provisions was based on sufficient evidence and compliance with accounting standards, accurately reflecting the company's financial status [3]. - The board approved the use of self-owned assets as collateral for bank credit applications to meet operational funding needs, ensuring no significant financial risk to the company [4]. Group 3: Upcoming Shareholder Meeting - The board has scheduled the first extraordinary general meeting of 2025 for September 9, 2025, to discuss the collateralization proposal, combining on-site and online voting methods [5].

Core Points - The company held its 16th meeting of the second supervisory board on August 21, 2025, where all three supervisors attended, confirming the meeting's legality and effectiveness [1] - The supervisory board unanimously agreed that the procedures for preparing and reviewing the 2025 semi-annual report complied with relevant laws and regulations, and the report accurately reflects the company's actual situation [1][2] - The board confirmed that the management and use of raised funds complied with regulatory requirements, with no violations noted [2] - The supervisory board approved the use of idle raised funds for cash management, which is expected to enhance fund utilization efficiency and generate investment returns [2][3] - The board agreed that the provision for asset impairment was in line with accounting standards and accurately reflects the company's financial status [3] - The decision to use self-owned assets as collateral for bank credit applications was deemed beneficial for the company's development and compliant with relevant regulations [3] - The proposals will be submitted for review at the company's first extraordinary general meeting of 2025 [4]

证券代码：688293 证券简称：奥浦迈 公告编号：2025-068 上海奥浦迈生物科技股份有限公司 关于 2025 年半年度计提资产减值准备的公告 （二）资产减值损失——存货跌价损失 根据《上海证券交易所科创板股票上市规则》《企业会计准则》等相关法律 法规的规定，为真实、准确、公允的反映上海奥浦迈生物科技股份有限公司（以 下简称"奥浦迈"或"公司"）2025年半年度的财务状况及经营情况，基于谨慎性原 则，公司对合并报表范围内截至2025年6月30日的各类资产进行减值测试，对存 在减值迹象的有关资产计提了减值准备。现将相关情况公告如下： 一、计提资产减值准备的情况概述 公司2025年半年度拟计提信用减值损失和资产减值损失共计639.11万元，具 体情况如下表： | | | 单位：万元 | 币种：人民币 | | | --- | --- | --- | --- | --- | | | 项目 | 2025 | 年半年度预计计提金额 | | | 信用减值损失 | | 应收账款坏账损失 | | 430.61 | | 资产减值损失 | | 存货跌价损失 | | 208.50 | | | 合计 | | 639.11 | | ...

Summary of Key Points Core Viewpoint - The company has reported a total impairment loss of 2.1284 million yuan for the first half of 2025, reflecting a cautious approach to financial reporting and adherence to accounting standards [1][2][3]. Group 1: Impairment Preparation Overview - The company has recognized a total of 2.1284 million yuan in credit and asset impairment losses for the first half of 2025, based on the principle of prudence [1]. - The impairment losses include 8.5173 million yuan attributed to credit losses and 6.3889 million yuan related to inventory impairment [2]. Group 2: Impact of Impairment Preparation - The impairment preparation will affect the company's consolidated profit by 2.1284 million yuan, aligning with the company's actual financial situation and accounting standards [3]. - The company emphasizes that this impairment does not involve changes in accounting methods and does not harm the interests of the company or its shareholders [3].

| 证券代码：600548 | 股票简称：深高速 | | | 公告编号：临 | 2025-075 | | --- | --- | --- | --- | --- | --- | | 债券代码：188451 | 债券简称：21 | 深高 | 01 | | | | 债券代码：185300 | 债券简称：22 | 深高 | 01 | | | | 债券代码：240067 | 债券简称：G23 | 深高 | 1 | | | | 债券代码：241018 | 债券简称：24 | 深高 | 01 | | | | 债券代码：241019 | 债券简称：24 | 深高 | 02 | | | | 债券代码：242050 | 债券简称：24 | 深高 | 03 | | | | 债券代码：242539 | 债券简称：25 | 深高 | 01 | | | | 债券代码：242780 | 债券简称：25 | 深高 | Y1 | | | | 债券代码：242781 | 债券简称：25 | 深高 | Y2 | | | | 债券代码：242972 | 债券简称：25 | 深高 | Y3 | | | 债券代码：242973 债券简称：25 深高 ...

证券代码：600336 证券简称：澳柯玛 编号：临 2025－030 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 澳柯玛股份有限公司九届十六次董事会于 2025 年 8 月 22 日召开，本次会议以通讯 方式通知、召开和表决，应参与表决董事 9 人，实际参与表决董事 9 人，本次会议由公 司董事长主持，符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 会议经审议，通过如下决议： 第一项、审议通过《关于公司 2025 年半年度报告及摘要的议案》，9 票同意，0 票 反对，0 票弃权。 本议案已经公司董事会审计委员会审议并全体通过。 第二项、审议通过《关于计提资产减值准备的议案》，9 票同意，0 票反对，0 票弃 权。 具体详见同日刊登在上海证券交易所网站上的公司《信息披露暂缓与豁免业务内部 管理制度》 （2025 年修订）。 第五项、审议通过《关于制定公司 <市值管理制度> 的议案》，9 票同意，0 票反对， 为切实加强公司市值管理工作，规范公司市值管理行为，维护公司、投资者及其他 利益相关者的合法权益，同意公 ...